Any current/future new fundraising through debt or equity?

Current borrowings stand at around Rs. 400+ crores. Borrowings are expected to increase by about Rs. 100-125 crores in the current financial year. This would keep the debt-to-equity ratio roughly in the range of 0.23 to 0.25. There is no mention of any immediate plans for equity fundraising. Promoter group has done some minor selling of shares recently but no large change in promoter holding is expected. Overall control of the company will not be affected by any promoter selling. No explicit discussion on future fundraising outside the mentioned debt increase was provided.

Any current/future capex/capital investment/strategic investment?

FY'25 CAPEX: Around Rs. 400 crores spent. FY'26 CAPEX guidance: Rs. 400-450 crores planned. Major CAPEX break-up for Rs. 800-850 crores cumulative over FY'25 and FY'26: - Atali Greenfield project: Rs. 400-425 crores. - Xanthine capacity expansion: Rs. 150 crores. - Solar plant: Rs. 85 crores. - Other smaller projects and R&D: approx. Rs. 40 crores annually. Atali project mechanical completion expected by end of current quarter; operational ramp-up phased through FY'26. Xanthine capacity expansion (to 9,000 MT) commissioned phased in H2 FY'26, fully operational by Q1 FY'27. Solar plant

Future growth expectations in sales/revenue/volumes?

The company targets around 15% revenue growth in FY'26. CDMO business is expected to grow 30%-40% in FY'26, contributing approximately 15%-16% of total revenue. Xanthine business aims for Rs. 1,000 crore to Rs. 1,250 crore in revenue with 80%-90% capacity utilization by FY'29. API & Intermediates segment growth driven by regulated markets and new product launches, particularly anti-cancer and anti-diabetic drugs. New products and launches expected over next 2-3 years will contribute to growth, strengthening market share. Atali plant commercialization expected by FY'26 end, with phase

Future growth expectations in earnings/operating earnings/profits/EPS?

FY'26 EBITDA growth guidance: 12% to 15% over the higher base of FY'25, supported by higher-margin products, process efficiencies, and volume growth. FY'25 EBITDA grew 20% YoY; PAT grew 26% YoY. Strong topline growth expected with 15% revenue growth guidance. CDMO business expected to grow 30%-40% in FY'26, contributing approx. 15%-16% of total revenue next year. Xanthine segment expected to reach Rs. 1000-1250 crores in revenue by full utilization (Q1 FY'27), driven by regulated pharma market growth. API segment growth supported by new launches and increasing market share in regulat

Current/ Expected Orderbook/ Pending Orders?

Aarti Pharmalabs is currently working with 21 customers in the CDMO/CMO segment. The number of active projects has increased to 61 (from 56 last quarter). Out of these, 33 projects are at the commercial stage, and 27 are under various development stages at the customer's end. Approximately 70-75% of the commercialized projects contributed to revenue in FY'25. The company focuses on both primary and secondary supplier roles in these projects and values both for commercial success. There is confidence in CDMO business growth with guidance of 30% to 40% growth. No explicit pending orderbook value

IN US

Sale is live|00:00:00left today

Aarti Pharmalabs LtdQ1 FY25Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹691P/E: 29.9Market Cap: ₹6.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company targets around 15% revenue growth in FY'26.
→CDMO business is expected to grow 30%-40% in FY'26, contributing approximately 15%-16% of total revenue.
→Xanthine business aims for Rs. 1,000 crore to Rs. 1,250 crore in revenue with 80%-90% capacity utilization by FY'29.
→API & Intermediates segment growth driven by regulated markets and new product launches, particularly anti-cancer and anti-diabetic drugs.
→New products and launches expected over next 2-3 years will contribute to growth, strengthening market share.
→Atali plant commercialization expected by FY'26 end, with phased operationalization supporting capacity expansion.
→Long-term 3-year growth guidance of 12%-15% EBITDA with focus on bottom-line improvement and process efficiencies.
→Revenue growth supported by strategic backward integration and broadening customer base (currently 21 customers in CDMO).

Margin guidance

Category 3

→FY'26 EBITDA growth guidance: 12% to 15% over the higher base of FY'25, supported by higher-margin products, process efficiencies, and volume growth.
→FY'25 EBITDA grew 20% YoY; PAT grew 26% YoY.
→Strong topline growth expected with 15% revenue growth guidance.
→CDMO business expected to grow 30%-40% in FY'26, contributing approx. 15%-16% of total revenue next year.
→Xanthine segment expected to reach Rs. 1000-1250 crores in revenue by full utilization (Q1 FY'27), driven by regulated pharma market growth.
→API segment growth supported by new launches and increasing market share in regulated exports.
→Long-term aspiration for capacity utilization of 80%-90% in Xanthine over three years.
→Medium-term revenue growth target ~15% annually for next 3 years, with current year guidance at 12%-15% EBITDA growth indicating some conservatism.
→Ongoing product innovation and new molecule launches in API and CDMO expected to drive earnings expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Current borrowings stand at around Rs. 400+ crores.
→Borrowings are expected to increase by about Rs. 100-125 crores in the current financial year.
→This would keep the debt-to-equity ratio roughly in the range of 0.23 to 0.25.
→There is no mention of any immediate plans for equity fundraising.
→Promoter group has done some minor selling of shares recently but no large change in promoter holding is expected.
→Overall control of the company will not be affected by any promoter selling.
→No explicit discussion on future fundraising outside the mentioned debt increase was provided.

Order book

→Aarti Pharmalabs is currently working with 21 customers in the CDMO/CMO segment.
→The number of active projects has increased to 61 (from 56 last quarter).
→Out of these, 33 projects are at the commercial stage, and 27 are under various development stages at the customer's end.
→Approximately 70-75% of the commercialized projects contributed to revenue in FY'25.
→The company focuses on both primary and secondary supplier roles in these projects and values both for commercial success.
→There is confidence in CDMO business growth with guidance of 30% to 40% growth.
→No explicit pending orderbook value mentioned, but the active projects and customer base indicate a healthy pipeline.

Capex plans

Yes

→FY'25 CAPEX: Around Rs. 400 crores spent.
→FY'26 CAPEX guidance: Rs. 400-450 crores planned.
→Major CAPEX break-up for Rs. 800-850 crores cumulative over FY'25 and FY'26:
→ - Atali Greenfield project: Rs. 400-425 crores.
→ - Xanthine capacity expansion: Rs. 150 crores.
→ - Solar plant: Rs. 85 crores.
→ - Other smaller projects and R&D: approx. Rs. 40 crores annually.
→Atali project mechanical completion expected by end of current quarter; operational ramp-up phased through FY'26.
→Xanthine capacity expansion (to 9,000 MT) commissioned phased in H2 FY'26, fully operational by Q1 FY'27.
→Solar plant payback expected in about 3.5 to 4 years, with cost savings materializing in FY'26.
→Additional capacity expansions planned at Atali with brownfield expansions enabling quicker capacity additions in ~12 months.
→Focus on backward integration and new molecules with patent expiry in 3-5 years.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Pharmalabs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aarti Pharmalabs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio